NovaBridge Biosciences (NBP) Assets (2018 - 2026)
NovaBridge Biosciences (NBP) posted quarterly Assets of $260.5 million for Q4 2025, up 22.49% year-over-year from $212.7 million in Q4 2024, and down 6.09% quarter-over-quarter from $277.4 million in Q3 2025.
Analysis
NovaBridge Biosciences (NBP) Assets (2018 - 2026) Analysis & Trends
NovaBridge Biosciences (NBP) has reported Assets for 8 consecutive years, with $260.5 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Assets rose 22.49% year-over-year to $260.5 million; the TTM figure through Dec 2025 stood at $260.5 million (up 22.49% YoY), while the FY2025 annual figure was $260.5 million, up 22.49% from the prior year.
- Assets eased to $260.5 million in Q4 2025 per NBP's latest filing, from $277.4 million in the prior quarter.
- Across five years, Assets topped out at $952.2 million in Q2 2021 and bottomed at $206.7 million in Q2 2025.
- Historically, Assets has averaged $434.3 million across 5 years, with a median of $277.4 million in 2025.
- Annual changes were most pronounced in 2021 — Assets surged 228.37% — and 2024, when it tumbled 47.59%.
- NovaBridge Biosciences' Assets stood at $876.1 million in 2021, then plunged by 34.62% to $572.8 million in 2022, then slumped by 36.64% to $362.9 million in 2023, then tumbled by 41.4% to $212.7 million in 2024, then climbed by 22.49% to $260.5 million in 2025.
- Business Quant data shows NBP's Assets at $260.5 million in Q4 2025, $277.4 million in Q3 2025, and $206.7 million in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 10.03 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 10.96 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 4.32 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 9.18 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 5.56 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 19.82 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 2.10 Bn |
| 10 | NovaBridge Biosciences | 197.68 Mn | 197.68 Mn | - | 231.54 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 231.54 Mn |
| Dec 31, 2025 | 260.52 Mn |
| Sep 30, 2025 | 277.41 Mn |
| Jun 30, 2025 | 206.71 Mn |
| Mar 31, 2025 | 208.94 Mn |
| Dec 31, 2024 | 212.68 Mn |
| Sep 30, 2024 | 232.68 Mn |
| Jun 30, 2024 | 253.83 Mn |
| Dec 31, 2023 | 362.91 Mn |
| Jun 30, 2023 | 484.29 Mn |
| Dec 31, 2022 | 572.77 Mn |
| Jun 30, 2022 | 745.22 Mn |
| Dec 31, 2021 | 876.08 Mn |
| Jun 30, 2021 | 952.21 Mn |
| Dec 31, 2020 | 955.73 Mn |
| Sep 30, 2020 | 633.04 Mn |
| Jun 30, 2020 | 289.98 Mn |
| Dec 31, 2019 | 246.53 Mn |
| Dec 31, 2018 | 343.63 Mn |